natgillin/translations-raw huggingface dataset:
Tabellen nedenfor viser hyppighed og sværhedsgrad af de bivirkninger, der blev betragtet som muligvis relaterede til studielægemidlet, og som blev indberettet hos ≥ 5 % af de patienter med ovariecancer, der blev randomiseret til at få Yondelis 1,1 mg/m2/PLD 30 mg/m2 i det pivotale studie ET743-OVA-301.
The table below provides the frequency and severity of undesirable effects considered possibly related to study medicinal product and reported in ≥ 5% of patients with ovarian cancer randomised to receive Yondelis 1.1 mg/m2/PLD 30 mg/m2 in the pivotal trial ET743-OVA-301.
Tabellen nedenfor viser udvikling af hiv-1 protease-mutationer og tab af følsomhed for PI’er i forbindelse med virologisk svigt ved endepunktet i studierne ARTEMIS, ODIN og TITAN.
The table below shows the development of HIV-1 protease mutations and loss of susceptibility to PIs in virologic failures at endpoint in the ARTEMIS, ODIN and TITAN trials.
Tabellen nedenfor viser udvikling af mutationer og tab af følsomhed for PI’er i forbindelse med virologisk svigt ved endepunktet i studierne ARTEMIS, ODIN og TITAN.
The table below shows the development of mutations and loss of susceptibility to PIs in virologic failures at endpoint in the ARTEMIS, ODIN and TITAN trials.
Tabellen nedenfor viser udviklingen af hiv-1 protease-mutationer og resistens over for PI’er ved virologiske svigt ved endepunktet i GS-US-216-130-studiet.
The table below shows the development of HIV-1 protease mutations and resistance to PIs in virologic failures at endpoint in the GS-US-216-130 trial.
Tabellen nedenfor viser virkningsdataene fra 48 ugers og 96 ugers analyserne fra de samlede
The table below shows the efficacy data of the 48-week and 96-week analyses from the pooled
Tabellen nedenfor viser virkningsdataene fra 48-ugers- og 96 ugers analyserne fra de samlede
The table below shows the efficacy data of the 48-week and 96-week analyses from the pooled
Tabellen nedenfor viser virkningsdataene fra 48-ugers- og 96-ugers-analyserne fra de samlede
The table below shows the efficacy data of the 48-week and 96-week analyses from the pooled
Tabellen nedenfor viser, at hyppigheden af grad 4 neutropeni, febril neutropeni og neutropenisk infektion var lavere hos patienter, der fik G-CSF profylaktisk, efter det blev gjort obligatorisk i TAC- armen i GEICAM-forsøget.
Febrile neutropenia and neutropenic infection occurred in 17.2% and 13.5% of patients respectively, regardless of G-CSF use.
Tabellen nedenfor viser, at hyppigheden af grad 4 neutropeni, febril neutropeni og neutropenisk infektion var lavere hos patienter, der fik G-CSF profylaktisk, efter det blev gjort obligatorisk i TAC- armen i GEICAM-studiet.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm – GEICAM study.
Tabellen nedenfor viser, at hyppigheden af grad 4 neutropeni, febril neutropeni og neutropenisk infektion var lavere hos patienter, der fik G-CSF profylaktisk, efter det blev gjort obligatorisk i TAC- armen i GEICAM-studiet.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm-GEICAM study.
Tabellen nedenfor viser, at hyppigheden af grad 4 neutropeni, febril neutropeni og neutropenisk infektion var lavere hos patienter, der fik G-CSF profylaktisk, efter det blev gjort obligatorisk i TAC- armen i GEICAM-studiet.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm. – GEICAM study.
Tabellen nedenfor viser, at hyppigheden af grad 4 neutropeni, febril neutropeni og neutropenisk infektion var lavere hos patienter, der fik G-CSF profylaktisk, efter det blev gjort obligatorisk i TACarmen i GEICAM-studiet.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm. – GEICAM study.
Tabellen nedenfor viser, at hyppigheden af grad 4-neutropeni, febril neutropeni og neutropenisk infektion var lavere hos patienter, der fik G-CSF profylaktisk, efter det blev gjort obligatorisk i TAC- armen i GEICAM-studiet.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm – GEICAM study.
Tabellen nedenfor viser, hvor ofte du sæ dvanligvis vil få denne medicin.
The table below shows how often you will usually have this medicine.
Tabellen nedenfor viser, hvor ofte du sædvanligvis vil få denne medicin.
The table below shows how often you will usually have this medicine.
Tabelliste over bivirkninger
Tabulated list of adverse reactions
Tabelliste over bivirkninger:
Tabular Listing of adverse events:
Tabeloversigt af bivirkninger
Tabulated list of adverse reactions
Tabeloversigt over bivirkninger
Tabulated summary of adverse reactions
Tabet i visus var generelt reversibelt inden for 2 uger uden intervention.
Visual acuity decreases were generally reversible within 2 weeks without intervention.
Table 1 - Væsentligste resultater (for den godkendte dosis, ITT-population)
Table 1 - Main Results ( for the approved dose, ITT population)
Table 10 Prædiktiv værdi af virologisk respons under behandling med peginterferon alfa-2b 1,5 µg/kg/ribavirin 800-1.400 mg kombinationsterapi
Table 10 Predictive Value of In-Treatment Virologic Response while on peginterferon alfa-2b 1.5 µg/kg/ Ribavirin 800-1,400 mg Combination Therapy
Table 12: Hazard ratio og 95 % CI for apopleksi/systemisk emboli i delpopulationer
Table 12: Hazard Ratio and 95 % CI for stroke/SEE by subgroups
Table 13: Opgørelse af første forekomst af apopleksi eller systemisk emboli (primært endepunkt) i studiesperioden i RE-LY.
Table 13: Analysis of first occurrence of stroke or SEE (primary endpoint) during the study period in RE-LY.
Table 17: Halveringstid for total dabigatran hos raske og hos patienter med nedsat nyrefunktion.
Table 17: Half-life of total dabigatran in healthy subjects and subjects with impaired renal function.
Table 21: Halveringstid for total dabigatran hos raske og hos patienter med nedsat nyrefunktion.
Table 21: Half-life of total dabigatran in healthy subjects and subjects with impaired renal function.
Table 3 ACR-respons i kliniske studier RA-I og RA-II
Table 3 ACR response in clinical trials RA-I and RA-II
Table 4 Virkning i den totale studiepopulation og i en undergruppe af patienter, der aktuelt får ULT, og som ikke er i stand til at bruge hverken NSAID eller colchicin
Table 4 Efficacy for the overall study population and in a subgroup of patients currently using ULT and unable to use both NSAIDs and colchicine
Table 6 RADIANT-4 – Resultater for progressionsfri overlevelse
Table 6 RADIANT-4 – Progression-free survival results
Table 7: Responsrater: Studie 108
Table 7: Response rates: Study 108
Table 9: Halveringstid for total dabigatran hos raske og hos patienter med nedsat nyrefunktion.
Table 9: Half-life of total dabigatran in healthy subjects and subjects with impaired renal function.
Table 9: Opgørelse af første forekomst af apopleksi eller systemisk emboli (primært endepunkt) i studiesperioden i RE-LY.
Table 9: Analysis of first occurrence of stroke or SEE (primary endpoint) during the study period in RE-LY.
tablet
(Invented)
tablet
(PVC/PVDC/alu)
tablet
1/3
tablet
dose)
tablet
EU/1/08/475/011
tablet
EU/1/08/475/017
tablet
EU/1/09/551/016
tablet
EU/1/13/891/036
tablet
Film-coated tablet
tablet
name
Tablet
Tablet.
tablet (enkeltstyk)
Film-coated tablet
Tablet dosis
Tablet dose
tablet Filmovertrukket
Film-coated tablet
tablet Filmovertrukket tablet
Film-coated tablet
Tablet filmovertræk Polyvinylalkohol Titandioxid (E171) Macrogol (PEG 3350) Talcum
Tablet film coat Polyvinyl alcohol Titanium dioxide (E171) Macrogol (PEG 3350) Talc
tablet indeholder 6 mg mavacoxib.
tablet contains 6 mg of mavacoxib.
tablet med modificeret
Modified-release tablet
Tablet med modificeret udløsning
Modified-release tablets
Tablet med modificeret udløsning.
Modified-release tablet
tablet Oprymea 0,18 mg 3 gange om dagen tabletter Oprymea 0,088 mg 3 gange om dagen tablet Oprymea 0,35 mg 3 gange om dagen tabletter Oprymea 0,18 mg 3 gange om dagen
tablet Oprymea 0.18 mg three times a day tablets Oprymea 0.088 mg three times a day tablet Oprymea 0.35 mg three times a day tablets Oprymea 0.18 mg three times a day
tablet SIFROL 0,18 mg tabletter SIFROL 0,088 mg tablet SIFROL 0,35 mg tabletter SIFROL 0,18 mg ELLER
tablet SIFROL 0.18 mg OR tablets SIFROL tablet SIFROL 0.35 mg OR tablets SIFROL 0.18 mg OR
Tablet Tablet
Tablet
Tablet, filmovertrukket
Film-coated tablet
Tablet- terne tages om morgenen og aftenen.
It is taken morning and evening.
Tablet-filmovertræk Hypromellose (E 464)
Tablet film-coat Hypromellose (E464) Titanium dioxide (E171) Polyethylene glycol
Tablet-overtræk:
Tablet coat:
Tablet.
Tablet
Tablet:
Tablet
Tablet: Copovidon Sorbitanlaurat
Tablet: Copovidone Sorbitan laurate
Tablet: Mikrokrystallinsk cellulose, prægelatineret stivelse, hydroxypropylcellulose, butyleret hydroxytoluen, natriumstivelseglycolat og magnesiumstearat
Tablet core: microcrystalline cellulose, pregelatinised starch, hydroxypropyl cellulose, butylated hydroxytoluene, sodium starch glycolate and magnesium stearate
Tabletbeholde r (HDPE)
Bottle (HDPE)
Tabletbeholder
Bottle label
tabletbeholder
Pack size
Tabletbeholder
Tablet container
Tabletbeholder (flaske) af højdensitetspolyethylen (HDPE) indeholdende et tørremiddel af siliciumdioxid og en polyesterspiral.
High density polyethylene (HDPE) tablet container (bottle) containing a silica gel desiccant and a polyester coil.
Tabletbeholder (HDPE)
Bottle (HDPE)
Tabletbeholder (HDPE)
container (HDPE)
Tabletbeholder (HDPE)
Tablet container (HDPE)
Tabletbeholder - Lamivudin Teva Pharma B.V. 150 mg filmovertrukne tabletter
Tablet container – Lamivudine Teva Pharma B.V. 150 mg film-coated tablets
Tabletbeholder - Lamivudin Teva Pharma B.V. 300 mg filmovertrukne tabletter
Tablet container – Lamivudine Teva Pharma B.V. 300mg film-coated tablets
Tabletbeholder - Selvklæbende papiretiket – Rivastigmin Teva 1,5 mg hårde kapsler
Tablet container - Self-adhesive, paper label – Rivastigmine Teva 1.5 mg hard capsules
Tabletbeholder - Selvklæbende papiretiket – Rivastigmin Teva 3 mg hårde kapsler
Tablet container - Self-adhesive, paper label – Rivastigmine Teva 3 mg hard capsules
Tabletbeholder - Selvklæbende papiretiket – Rivastigmin Teva 4,5 mg hårde kapsler
Tablet Container - Self-adhesive, paper label – Rivastigmine Teva 4.5 mg hard capsules
Tabletbeholder - Selvklæbende papiretiket – Rivastigmin Teva 6 mg hårde kapsler
Tablet container - Self-adhesive, paper label – Rivastigmine Teva 6 mg hard capsules
Tabletbeholder 10 mg: 3 år.
Tablet containers 10 mg 3 years.
Tabletbeholder 15 mg: 3 år.
Tablet containers 15 mg 3 years.
Tabletbeholder 2,5 mg: 3 år.
Tablet containers 2.5 mg 3 years.
Tabletbeholder 20 mg: 3 år.
Tablet containers 20 mg 3 years.
Tabletbeholder 5 mg: 3 år.
Tablet containers 5 mg 3 years.
Tabletbeholder 7,5 mg: 3 år.
Tablet containers 7.5 mg 3 years.
Tabletbeholder af polypropylen med børnesikret polyethylen-låg med 100 & 500 filmovertrukne tabletter pr. tabletbeholder.
Polypropylene tablet containers with tamper evident polyethylene closure containing 100 & 500 film- coated tablets per tablet container.
Tabletbeholder af polypropylen med børnesikret polyethylen-låg med 100 filmovertrukne tabletter pr. tabletbeholder.
Polypropylene tablet containers with tamper evident polyethylene closure containing 100 film-coated tablets per tablet container.
Tabletbeholder af polypropylen med børnesikret polyethylen-låg med 250 & 500 filmovertrukne tabletter pr. tabletbeholder.
Polypropylene tablet containers with tamper evident polyethylene closure containing 250 & 500 film- coated tablets per tablet container.
Tabletbeholder af polypropylen med børnesikret polyethylen-låg med 250 & 500 filmovertrukne tabletter pr. tabletbeholder.
Polypropylene tablet containers with tamper evident polyethylene closure containing 250 & 500 tablets per tablet container.
tabletbeholder:
for tablet container:
Tabletbeholder:
Tablet container:
Tabletbeholder:
Tablet containers:
Tabletbeholder: 100 ml HDPE-bredhalset tabletbeholder, med skruelåg og integreret fugtbeholder indeholdende enten 30 eller 100 filmovertrukne tabletter.
Bottle: 100 ml HDPE-wide-necked bottle, with screw cap with integrated desiccant container, containing either 30 or 100 film-coated tablets.
Tabletbeholder: 100 ml HDPE-bredhalset tabletbeholder, med skruelåg og integreret fugtbeholder Indeholdende enten 30, 50 eller 100 filmovertrukne tabletter.
Bottle: 100 ml HDPE-wide-necked bottle, with screw cap with integrated desiccant container, containing either 30, 50 or 100 film-coated tablets.
Tabletbeholder: Hold tabletbeholderen tæt tillukket
Bottle: Keep the bottle tightly closed.
Tabletbeholder: Hold tabletbeholderen tæt tillukket.
Bottle: Keep the bottle tightly closed.
Tabletbeholdere: 30, 90 og 250 tabletter
Tablet containers: 30, 90 and 250 tablets
TABLETBEHOLDERETIKET
BOTTLE LABEL
Tabletbelægning
Tablet coating
TABLETGLAS
BO TTLE PACK
TABLETGLAS
Bottle
Tabletindhold: mikrokrystallinsk cellulose, vandfri lactose, hypromellose, croscarmellosenatrium, kolloid vandfri silica og magnesiumstearat. (Se punkt 2 med hensyn til indhold af lactose.)
Tablet contents: microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide anhydrous, magnesium stearate. (see section 2 for lactose content)
Tabletkern: Watervrij lactose
Tablet core:
Tabletkerne
Tablet core Mannitol (E421)
Tabletkerne
Tablets’ core
Tabletkerne (6 mg, 8 mg, 10 mg og 12 mg tabletter)
Tablet core (6 mg, 8 mg, 10 mg and 12 mg tablets)
Tabletkerne - mikrokrystallinsk cellulose (E460(i)), croscarmellosenatrium (E468), natriumstivlesesglycolat, crospovidon (E1202), stearinsyre (E570), magnesiumstearat (E470b), hydroxypropylcellulose (E463), silica (E551)
Tablet core - microcrystalline cellulose (E460(i)), croscarmellose sodium (E468), sodium starch glycolate, crospovidone (E1202), stearic acid (E570), magnesium stearate (E470b), hydroxypropyl cellulose (E463), silicon dioxide (E551)
Tabletkerne Copovidon
Tablet core Copovidone
Tabletkerne Copovidon Lactosemonohydrat
Tablet core Copovidone
Tabletkerne Croscarmellosenatrium Hydroxypropylcellulose Lactose (som monohydrat) Magnesiumstearat Mikrokrystallinsk cellulose Siliciumdioxid Natriumlaurilsulfat
Tablet core Croscarmellose sodium Hydroxypropyl cellulose Lactose (as monohydrate) Magnesium stearate Microcrystalline cellulose Silicon dioxide
Tabletkerne Croscarmellosenatrium Hydroxypropylcellulose Lactose monohydrat Magnesiumstearat Mikrokrystallinsk cellulose Natriumlaurilsulfat
Tablet core Croscarmellose sodium Hydroxypropyl cellulose Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sodium lauryl sulfate
Tabletkerne Croscarmellosenatrium Lactosemonohydrat Magnesiumstearat Mikrokrystallinsk cellulose Polysorbat 20
Tablet core Croscarmellose sodium Lactose monohydrate Magnesium stearate Microcrystalline cellulose Polysorbate 20
Tabletkerne Croscarmellosenatrium Macrogol 6000
Tablet core Croscarmellose sodium Macrogol 6000
Tabletkerne Croscarmellosenatrium Silica, kolloid vandfri Magnesiumstearat Hydroxypropylcellulose
Tablet core Croscarmellose sodium Colloidal anhydrous silica Magnesium stearate Hydroxypropylcellulose
Tabletkerne for 15 mg filmovertrukne tabletter Opadry II Orange 33G230001:
Tablet coat for 15 mg film-coated tablets Opadry II Orange 33G230001: Hypromellose 6cP
Tabletkerne for 20 mg filmovertrukne tabletter
Tablet coat for 20 mg film-coated tablets Opadry II Pink 33G240000: Hypromellose 6cP
Tabletkerne for 5 mg og 10 mg filmovertrukne tabletter Opadry II White 33G28435:
Tablet coat for 5 mg and 10 mg film-coated tablets Opadry II White 33G28435:
Tabletkerne for 5/10/15/20 mg filmovertrukne tabletter
Tablet cores for 5/10/15/20 mg film-coated tablets
Tabletkerne for 5/10/15/20 mg filmovertrukne tabletter:
Tablet cores for 5/10/15/20 mg film-coated tablets Lactose monohydrate
Tabletkerne for 5/10/15/20 mg filmovertrukne tabletter:
Tablet cores for 5/10/15/20 mg film-coated tablets:
Tabletkerne for 5/10/15/20 mg filmovertrukne tabletter: Mikrokrystallinsk cellulose
Tablet cores for 5/10/15/20 mg film-coated tablets: Microcrystalline cellulose
Tabletkerne Lactosemonohydrat
Lactose monohydrate
Tabletkerne Lactosemonohydrat
Lactose monohydrate Maize starch
Tabletkerne Lactosemonohydrat
Tablet core
Tabletkerne Lactosemonohydrat Majsstivelse Hydroxypropylcellulose Magnesiumstearat
Lactose monohydrate, Maize starch Hydroxypropyl cellulose Magnesium stearate
Tabletkerne Lactosemonohydrat Majsstivelse Prægelatineret majsstivelse
Lactose monohydrate Maize starch
Tabletkerne Mannitol
Tablet core Mannitol
Tabletkerne Mannitol (E421)
Tablet core Mannitol (E421)
Tabletkerne Mikrokrystallinsk cellulose
Tablet core Microcrystalline cellulose
Tabletkerne Mikrokrystallinsk cellulose Crospovidon type A Talkum
Tablet core Microcrystalline cellulose Crospovidone Type A Talc
Tabletkerne Mikrokrystallinsk cellulose Hydroxypropylcellulose
Tablet core microcrystalline cellulose
Tabletkerne Mikrokrystallinsk cellulose Hydroxypropylcellulose
Tablet core microcrystalline cellulose hydroxypropylcellulose
Tabletkerne Mikrokrystallinsk cellulose Kolloid vandfrit silica Crospovidon Magnesiumstearat
Tablet core Microcrystalline cellulose Colloidal anhydrous silica Crospovidone Magnesium stearate
Tabletkerne Mikrokrystallinsk cellulose Kolloid vandfrit silica Crospovidon Magnesiumstearat Hypromellose
Tablet core Microcrystalline cellulose Colloidal anhydrous silica Crospovidone Magnesium stearate Hypromellose
Tabletkerne Mikrokrystallinsk cellulose Lactose, vandfri Crospovidon, type A Magnesiumstearat
Tablet core Microcrystalline cellulose Lactose, anhydrous Crospovidone, type A Magnesium stearate
Tabletkerne Mikrokrystallinsk cellulose Lactosemonohydrat Croscarmellosenatrium Magnesiumstearat.
Tablet core Microcrystalline cellulose Lactose monohydrate Croscarmellose sodium Magnesium stearate.
Tabletkerne Mikrokrystallinsk cellulose Mannitol
Tablet core Microcrystalline cellulose Mannitol
Tabletkerne Mikrokrystallinsk cellulose Povidon (K30)
Tablet core Microcrystalline cellulose Povidone (K30)
Tabletkerne Mikrokrystallinsk cellulose Povidon (K30) Croscarmellosenatrium Magnesiumstearat
Tablet core Microcrystalline cellulose Povidone (K30) Croscarmellose sodium Magnesium stearate
Tabletkerne Mikrokrystallinsk cellulose Povidon K-30 Magnesiumstearat Croscarmellosenatrium
Tablet core Microcrystalline cellulose Povidone K-30 Magnesium stearate Croscarmellose sodium
Tabletkerne Natriumlaurilsulfat
Tablet core
Tabletkerne Povidon K30 Magnesiumstearat
Tablet core Povidone K30 Magnesium stearate
Tabletkerne Vandfri lactose
Tablet core Anhydrous lactose
Tabletkerne Xylitol
Tablet core Xylitol
Tabletkerne – CHAMPIX 0,5 mg og 1 mg filmovertrukne tabletter
Tablet Core - CHAMPIX 0.5 mg and 1 mg film-coated tablets Cellulose, Microcrystalline
Tabletkerne:
Core:
Tabletkerne: Arginin Copovidon Magnesiumstearat Majsstivelse
Tablet core Arginine Copovidone Magnesium stearate Maize starch
Tabletkerne: Arginin, copovidon, magnesiumstearat, majsstivelse, kolloid vandfri silica.
Tablet core: arginine, copovidone, magnesium stearate, maize starch, silica, colloidal anhydrous.
Tabletkerne: cellulose, mikrokrystallinsk, croscarmellosenatrium, hypromelloseacetat- succinat, povidon K30, natriumlaurilsulfat, magnesiumstearat
Tablet core: cellulose, microcrystalline; croscarmellose sodium; hypromellose acetate succinate; povidone K30; sodium laurilsulfate; magnesium stearate
Tabletkerne: Cellulose, mikrokrystallinsk, crospovidon, hypromellose, lactosemonohydrat, magnesiumstearat og natriumlaurilsulfat (se sidst i pkt.
Tablet core: cellulose microcrystalline, crospovidone, hypromellose, lactose monohydrate, magnesium stearate and sodium laurilsulfate (see end of section 2 for further information on lactose).
Tabletkerne: Cellulose, mikrokrystallinsk, lactosemonohydrat (se punkt 2 – Kalydeco indeholder lactose), hypromelloseacetatsuccinat, croscarmellosenatrium, natriumlaurilsulfat, silica, kolloid og magnesiumsterat.
Tablet core: Cellulose, microcrystalline; lactose monohydrate (see section 2 – Kalydeco contains lactose); hypromellose acetate succinate; croscarmellose sodium; sodium laurilsulfate; colloidal silicon dioxide; and magnesium stearate.
Tabletkerne: cellulose, mikrokrystallinsk; calciumhydrogenphosphat, vandfrit; natriumstivelsesglycolat; magnesiumstearat.
Tablet core: cellulose microcrystalline, calcium hydrogen phosphate anhydrous, sodium starch glycolate, magnesium stearate
Tabletkerne: copovidon, E-vitamin polyethylenglycolsuccinat, propylenglykolmonolaurat, sorbitanmonolaurat, kolloid vandfri silica(E551), natriumstearylfumarat.
Tablet core: copovidone, vitamin E polyethylene glycol succinate, propylene glycol monolaurate, sorbitan monolaurate, colloidal anhydrous silica (E551), sodium stearyl fumarate.
Tabletkerne: Croscarmellosenatrium Macrogol 6000
Tablet core: Croscarmellose sodium Macrogol 6000
Tabletkerne: Croscarmellosenatrium Magnesiumstearat
Tablet core: Croscarmellose sodium Magnesium stearate Maize starch
Tabletkerne: Croscarmellosenatrium Magnesiumstearat Majsstivelse
Tablet core: Croscarmellose sodium Magnesium stearate Maize starch
Tabletkerne: Croscarmellosenatrium Mikrokrystallinsk cellulose Natriumlaurilsulfat Hydroxypropylcellulose Lactosemonohydrat Magnesiumstearat
Tablet core Croscarmellose sodium Microcrystalline cellulose Sodium laurilsulfate Hydroxypropylcellulose Lactose monohydrate Magnesium stearate
tabletkerne: croscarmellosenatrium, hydroxypropylcellulose, vandfri lactose, magnesiumstearat og mikrokrystallinsk cellulose filmovertræk: macrogol (3350), polyvinylalkohol, talcum og titandioxid (E171).
tablet core: croscarmellose sodium, hydroxypropyl cellulose, lactose anhydrous, magnesium stearate, and microcrystalline cellulose film-coating: macrogol (3350), polyvinyl alcohol, talc, and titanium dioxide (E171).
Tabletkerne: Croscarmellosenatrium, macrogol 6000, kolloid vandfri silica, magnesiumstearat.
Tablet core: croscarmellose sodium, macrogol 6000, silica colloidal anhydrous, magnesium stearate.
Tabletkerne: Croscarmellosenatrium, mikrokrystallinsk cellulose, natriumlaurilsulfat, hydroxypropyl- cellulose, lactosemonohydrat, magnesiumstearat
Tablet core: Croscarmellose sodium, Microcrystalline cellulose, Sodium laurilsulfate, Hydroxypropylcellulose, Lactose monohydrate, Magnesium stearate
Tabletkerne: Crospovidon Magnesiumstearat
Tablet core: Crospovidone Magnesium stearate Microcrystalline cellulose
Tabletkerne: Hydroxypropylcellulose (E463), mannitol (E421), crospovidone, (type A), citronsyremonohydrat, mikrokrystallinsk cellulose, macrogol 6000, stearinsyre, talcum
Tablet core: hydroxypropylcellulose (E463), mannitol (E421), crospovidone (type A), citric acid monohydrate, microcrystalline cellulose, macrogol 6000, stearic acid, talc
Tabletkerne: Hydroxypropylcellulose Magnesiumstearat
Tablet core: Hydroxypropylcellulose Magnesium stearate
Tabletkerne: Hypromellose (E464), majsstivelse, crospovidon (E1202), poloxamer 407, lactosemonohydrat, kolloid vandfri silica, magnesiumstearat (E572).
Tablet core Hypromellose (E464), maize starch, crospovidone (E1202), poloxamer 407, lactose monohydrate, colloidal anhydrous silica, magnesium stearate(E572).
Tabletkerne: hypromellose, mikrokrystallinsk cellulose, kolloid vandfri silica, magnesiumstearat; filmovertræk: hypromellose, titandioxid (E-171), polyethylenglykol 400
Tablet core: hypromellose, microcrystalline cellulose, silica colloidal anhydrous, magnesium stearate; film coat: hypromellose, titanium dioxide (E-171), polyethylene glycol 400